Europska Unija - hrvatski - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostatske neoplazme - endokrinska terapija - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

clinres farmacija d.o.o. - degareliks - prašak i rastvarač za rastvor za injekciju - 80 mg/1 viala - 1 bočica sa praškom za rastvor za injekciju sadrži: 80 mg degareliksa (u obliku degareliks acetata)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

clinres farmacija d.o.o. - degareliks - prašak i rastvarač za rastvor za injekciju - 120 mg/1 viala - 1 bočica sa praškom za rastvor za injekciju sadrži: 120 mg degareliksa (u obliku degareliks acetata)

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatske neoplazme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.